IMVT
Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology · US
$36.95
−1.86%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 213.90x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 10.38x
- Price / sales
- 1075.70x
- Price / cash flow
- -18.42x
Enterprise value
- Enterprise value
- $6.8B
- EV / sales
- 963.26x
- EV / EBITDA
- -12.69x
- EV / EBIT
- -12.23x
- Market cap
- $7.6B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026